Journal
JOURNAL OF CLINICAL MEDICINE
Volume 12, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/jcm12010200
Keywords
Kruppel-like factor 6; pancreatic cancer; prognosis; proliferation; metastasis; activating transcription factor 3
Categories
Ask authors/readers for more resources
This study investigates the role of KLF6 in pancreatic cancer (PAAD). The results show that KLF6 is downregulated in pancreatic cancer tissues and is associated with poor survival. Overexpression of KLF6 inhibits proliferation, metastasis, and epithelial-mesenchymal transition (EMT) in pancreatic cancer cells. It is discovered that KLF6 upregulates activating transcription factor 3 (ATF3) in PAAD.
Background: As a member of the Kruppel-like factor (KLFs) family, Kruppel-like factor 6 (KLF6) plays a critical role in regulating key cellular functions. Presently, scholars have proved the important role of KLF6 in the tumorigenesis of certain cancers through a large number of experiments. However, gaps still remain in our knowledge of the role of KLF6 in pancreatic cancer (PAAD). Therefore, this paper mainly investigates the role of KLF6 in the progression of pancreatic cancer. Methods: The expression pattern of KLF6 in pancreatic cancer was explored in pancreatic cancer tissues and cell lines. Then, we investigated the prognostic value of KLF6 in pancreatic cancer by immunohistochemical assays. Next, Cell Counting Kit-8 (CCK8) and clone information assays were employed to explore the proliferation of PAAD affected by KLF6. The metastasis and epithelial-mesenchymal transition (EMT) abilities affected by KLF6 were identified through transwell invasion as well as migration assays and western blots. Finally, the TRRUST tool was used to analyze the potential targeted genes of KLF6. The results were verified by Quantificational Real-time Polymerase Chain Reaction (qRT-PCR), western blot and rescue assays. Results: KLF6 expresses lowly in pancreatic cancer compared to corresponding normal tissues and relates to poor survival times. Overexpression of KLF6 inhibits the proliferation, metastasis, and EMT progression in pancreatic cancer cells. Further studies suggest that KLF6 could upregulate ATF3 in PAAD. Conclusions: Our results suggest that KLF6 can be a useful factor in predicting the prognosis of PAAD patients and that it inhibits the progression of pancreatic cancer by upregulating activating transcription factor 3 (ATF3).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available